Trastuzumab induces antibody-dependent cell-mediated cytotoxicity (ADCC) in HER-2-non-amplified breast cancer cell lines.
about
Mechanisms of resistance and sensitivity to anti-HER2 therapies in HER2+ breast cancerA nervous tumor microenvironment: the impact of adrenergic stress on cancer cells, immunosuppression, and immunotherapeutic responseSerial Measurements of Apoptotic Cell Numbers Provide Better Acceptance Criterion for PBMC Quality than a Single Measurement Prior to the T Cell Assay.Multiformat T-cell-engaging bispecific antibodies targeting human breast cancers.Targeting ADAM-17 with an inhibitory monoclonal antibody has antitumour effects in triple-negative breast cancer cells.Analysis of in vitro ADCC and clinical response to trastuzumab: possible relevance of FcγRIIIA/FcγRIIA gene polymorphisms and HER-2 expression levels on breast cancer cell lines.Combining targeted therapy with immunotherapy. Can 1+1 equal more than 2?Immunological off-target effects of standard treatments in gastrointestinal cancersExpanding the use of monoclonal antibody therapy of cancer by using ionising radiation to upregulate antibody targets.HER2-family signalling mechanisms, clinical implications and targeting in breast cancer.Cessation of targeted therapy after a complete response in BRAF-mutant advanced melanoma: a case series.Cardiotoxic drugs Herceptin and doxorubicin inhibit cardiac microvascular endothelial cell barrier formation resulting in increased drug permeability.Characterizing the effect of multiple Fc glycan attributes on the effector functions and FcγRIIIa receptor binding activity of an IgG1 antibody.Functionally Active Fc Mutant Antibodies Recognizing Cancer Antigens Generated Rapidly at High Yields.Endophilin A2 promotes HER2 internalization and sensitivity to trastuzumab-based therapy in HER2-positive breast cancers.Whole exome sequencing to identify genetic markers for trastuzumab-induced cardiotoxicity.Adding Pertuzumab to Trastuzumab and Taxanes in HER2 positive breast cancer.NK cell-mediated antibody-dependent cellular cytotoxicity is enhanced by tamoxifen in HER2/neu non-amplified, but not HER2/neu-amplified, breast cancer cells.Evaluation of analytical similarity between trastuzumab biosimilar CT-P6 and reference product using statistical analyses.Multivalent exposure of trastuzumab on iron oxide nanoparticles improves antitumor potential and reduces resistance in HER2-positive breast cancer cells.Investigation of antitumor activities of trastuzumab delivered by PLGA nanoparticles.
P2860
Q26772969-1F209807-842E-4BF8-AD66-5167E4848BF4Q35077524-FB057A81-2B90-45CD-B139-F7AFC20AA34EQ35237387-F404F8C3-1799-4ACE-9FF5-66793620782DQ35822172-0B2DC615-76AB-491C-B89A-FFE211B92FE6Q36086816-597E86E4-5976-4FB5-87F5-039B24CA2CA9Q36139709-BA132AE8-16B4-4C15-940C-677B4C789309Q37066925-BD2AE758-08D1-430A-AFEC-66C46A3F3BF5Q37404086-A460BD35-CDBD-439E-9902-5F465BD17912Q37650735-7399C53C-8202-4A4B-93AE-D1C6905A71FDQ38301236-4E73D79D-978E-43BE-B476-9E8BB134A6BEQ39316588-E2E6EBB3-E1DB-4D06-B14B-522038CE0BA0Q39472056-137735CF-0F32-4621-9519-30EC82CB914CQ39782184-7B8B3104-4FBD-43BC-8C5C-323174429E13Q41673094-17CD529D-7C0E-4AFE-BF10-C93F85707C68Q42281218-DA34D7CC-5C7B-4AF5-A661-DA21B8329F08Q47286758-89B89285-DB33-49F2-BA4E-DFF53175571FQ47813594-FE6D74C4-8876-4A8F-BE49-AD7DD728BE86Q51543249-E22D6F7D-4229-44E2-A26F-7F295896102FQ52684751-625FE262-48D4-4199-BF58-A5F9509AA13CQ52716381-6F18D76A-2B41-48A4-80B7-985351313AFBQ54921136-89D6F927-3E9F-4C03-BE2B-10798D450A46
P2860
Trastuzumab induces antibody-dependent cell-mediated cytotoxicity (ADCC) in HER-2-non-amplified breast cancer cell lines.
description
2011 nî lūn-bûn
@nan
2011年の論文
@ja
2011年学术文章
@wuu
2011年学术文章
@zh-cn
2011年学术文章
@zh-hans
2011年学术文章
@zh-my
2011年学术文章
@zh-sg
2011年學術文章
@yue
2011年學術文章
@zh
2011年學術文章
@zh-hant
name
Trastuzumab induces antibody-d ...... fied breast cancer cell lines.
@en
Trastuzumab induces antibody-dependent cell-mediated cytotoxicity
@nl
type
label
Trastuzumab induces antibody-d ...... fied breast cancer cell lines.
@en
Trastuzumab induces antibody-dependent cell-mediated cytotoxicity
@nl
prefLabel
Trastuzumab induces antibody-d ...... fied breast cancer cell lines.
@en
Trastuzumab induces antibody-dependent cell-mediated cytotoxicity
@nl
P2093
P2860
P356
P1433
P1476
Trastuzumab induces antibody-d ...... fied breast cancer cell lines.
@en
P2093
D M Collins
F O'Sullivan
N O'Donovan
P M McGowan
P2860
P304
P356
10.1093/ANNONC/MDR484
P577
2011-11-05T00:00:00Z